BIND Therapeutics has amended its development and commercialization collaboration with Amgen to extend Amgen’s exercise option by six months. The global collaboration entails the development and commercialization of a kinase inhibitor nanomedicine to treat a range of solid tumors based on BIND’s Accurin platform for targeted and programmable nanomedicines and Amgen’s undisclosed proprietary kinase inhibitor.   Amgen’s option period to select a novel Accurin candidate for further development has ...